Trafalgar International GCAN

The Greater Cannabis Company, Inc. is engaged in the development and commercialization of innovative cannabinoid therapeutics utilizing transmucosal and transdermal delivery technologies. The company was originally organized as a limited liability company and later became a wholly owned subsidiary of another entity before acquiring Green C Corporation, which held an exclusive worldwide license for an eluting transmucosal patch platform. After the acquisition, the company shifted its focus to the development and commercialization of cannabinoid based therapies, abandoning prior e commerce and advertising activities. In October 2021 it entered into a license agreement with Shaare Zedek Scientific Ltd. to obtain rights to a novel cannabinoid therapeutic targeting autism, schizophrenia, Parkinson’s disease, Alzheimer’s disease and other neuropsychiatric disorders. The company has completed preclinical studies for this therapeutic and has received regulatory clearance to proceed with a Phase 2 clinical trial, pending the sourcing of the required active pharmaceutical ingredient.

The company generates revenue primarily through licensing agreements that provide upfront fees, milestone payments and future royalties on product sales. Under its agreement with Shaare Zedek Scientific Ltd. it is entitled to annual licensing fees starting at $5,000, milestone payments of $75,000 for Phase 2 trial initiation, $200,000 for Phase 3 trial initiation and $300,000 upon first regulatory approval. The agreement also provides tiered royalties ranging from 2.25% to 3% on dietary supplement sales and 1% to 2% on drug product sales, with royalty caps applied at defined sales thresholds. To advance the therapeutic into clinical testing the company will need to raise additional funds to finance the Phase 2 trial, which is expected to last between 18 and 24 months from start to completion. In support of its research and development efforts the company plans to allocate approximately $250,000 from financing proceeds toward sample production, preclinical studies and the formulation of new cannabinoid based products.

The Greater Cannabis Company, Inc. competes in the cannabinoid therapeutics space alongside companies such as Jazz Pharmaceuticals and Zynerba Pharmaceuticals, which also develop cannabinoid based treatments for neurological conditions. Many other participants in the broader cannabis industry include producers of cannabis plants, manufacturers of edible products and developers of alternative delivery methods. The company’s competitive advantage stems from its exclusive worldwide license for an eluting transmucosal patch platform that enables noninvasive delivery of cannabinoids across mucosal membranes. Additionally, the collaborative research agreement with Shaare Zedek Medical Center provides access to a novel cannabinoid therapy targeting autism, schizophrenia, Parkinson’s and Alzheimer’s disease, backed by ongoing clinical investigation led by a recognized pediatric neurologist. This combination of proprietary delivery technology and a differentiated therapeutic pipeline positions the company to address unmet medical needs in markets where traditional pharmaceutical options are limited.

The company’s intended customers include patients suffering from neuropsychiatric disorders who may benefit from its future therapeutic products. Healthcare providers such as physicians and clinics that treat neurological conditions represent another potential customer segment that could prescribe or administer the therapy upon regulatory approval. Manufacturers of dietary supplements and pharmaceutical products that incorporate the company’s licensed technology would generate royalty revenue based on sales of the final goods. Although no specific customer names have been disclosed, the company anticipates demand from both the medical nutrition sector and the broader pharmaceutical market seeking cannabinoid based solutions.